Research Papers: Gerotarget (Focus on Aging):
The protective effect of Epimedii Folium and Curculiginis Rhizoma on Alzheimer’s disease by the inhibitions of NF-κB/MAPK pathway and NLRP3 inflammasome
Metrics: PDF 789 views | HTML 1456 views | ?
Zhou Lan1, Guangjing Xie2, Meng Wei1, Ping Wang2 and Lvyi Chen3
1 School of Pharmacy, Hubei University of Chinese Medicine, Wuhan , P. R. China
2 School of Basic Medicine, Hubei University of Chinese Medicine, Wuhan, P. R. China
3 School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan, P. R. China
Lvyi Chen, email:
Ping Wang, email:
Keywords: the water extracts of Epimedii Folium and Curculiginis Rhizoma (EX), Alzheimer’s disease, amyloid β, neuroinflammation, Gerotarget
Received: August 23, 2016 Accepted: October 05, 2016 Published: May 23, 2017
The purpose of the current study was to explore the effects of the water extracts of Epimedii Folium and Curculiginis Rhizoma (EX) on Aβ-induced Alzheimer’s disease. Aβ1-42 was stereotaxically injected bilaterally into the dorsal hippocampus, and then the rats were orally received EX at the doses of 2 g/kg and 6 g/kg for 30 days. Behavior was monitored through Morris water maze test. The neuroprotective effect of EX were examined with methods of histochemistry and biochemistry. EX reduced the contents of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6) in hippocampus and cortex. EX also reduced the levels of malondialdehyde (MDA) and increased superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and glutathione peroxidase (GSH-Px) in the serum. Immunohistochemical analysis demonstrated that EX inhibited the expressions of NLRP3. In addition, we further confirmed that EX suppressed the expression of the NLRP3 inflammasome. EX inhibited the phosphorylations MAPKs, nuclear factor κB (NF-κB), myeloid differentiation factor 88(MyD88), cathepsin B. In conclusion, these results suggest that EX may be a potential agent for treating Alzheimer’s disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.